Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces today that it received the approvals of ANSM (French Drug Administration) and CPP (Patient Protection Committee) to start a Phase IIa clinical trial using its lead compound QGC001, a first-in-class drug candidate to treat hypertension.
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2014/11/QGC_PR_CPP-ANSM_QGC001_20141117_UK.pdf” target=”_blank” title=”Download pdf” size=”small” color=”red”]
